Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib.
Nazim Can DemircanÖzkan AlanTuğba Başoğlu TüylüTuğba Akın TelliRukiye ArıkanFurkan C ÇiçekÖzlem ErcelepMehmet Akif Ozturkİlknur Alsan ÇetinRabia Ergelenİlker TinayNalan Akgül BabacanSerap KayaFaysal DanePerran F YumukPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)
Charlson Comorbidity Index may be a valuable method to estimate prognosis and optimize therapy in patients with advanced renal cell carcinoma receiving first-line sunitinib or pazopanib.